BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30080131)

  • 1. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
    Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
    Casanova M; Bautista F; Campbell-Hewson Q; Makin G; Marshall LV; Verschuur AC; Cañete Nieto A; Corradini N; Ploeger BA; Brennan BJ; Mueller U; Zebger-Gong H; Chung JW; Geoerger B
    Clin Cancer Res; 2023 Nov; 29(21):4341-4351. PubMed ID: 37606641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
    J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
    Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
    J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
    Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
    J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
    Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
    Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.
    Schöffski P; Wang CC; Schöffski MP; Wozniak A
    Oncol Res Treat; 2024; 47(1-2):18-41. PubMed ID: 38016427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan dose schedule for the treatment of Ewing sarcoma.
    Slotkin EK; Meyers PA
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30005. PubMed ID: 36184748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
    Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM
    Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
    Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
    Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
    Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
    Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
    J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR project.
    Evans C; Shepherd L; Bryan G; Fulbright H; Crowther S; Wakeling S; Stewart A; Stewart C; Chisholm J; Gibson F; Phillips B; Morgan JE
    Int J Cancer; 2024 Apr; 154(7):1235-1260. PubMed ID: 38071594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common musculoskeletal tumors of childhood and adolescence.
    Arndt CA; Rose PS; Folpe AL; Laack NN
    Mayo Clin Proc; 2012 May; 87(5):475-87. PubMed ID: 22560526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cole KA; Ijaz H; Surrey LF; Santi M; Liu X; Minard CG; Maris JM; Voss S; Reid JM; Fox E; Weigel BJ
    Cancer; 2023 Jul; 129(14):2245-2255. PubMed ID: 37081608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
    Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
    Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.